PMID: 9661010Jul 14, 1998Paper

Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients

Antimicrobial Agents and Chemotherapy
A HishidaA Kitada

Abstract

The pharmacokinetics of cefdinir were investigated in six hemodialysis patients. For the present study, two tests were carried out, one with 4 h of hemodialysis and the other without hemodialysis. Cefdinir was given orally to each patient in a dose of 100 mg, and blood was collected serially for 48 h after dosing in the test without dialysis and for 72 h in the test with dialysis. In the test without dialysis, the maximum plasma concentration (Cmax) was 2.36 +/- 0.53 micrograms/ml (mean +/- standard deviation) and the time to Cmax was 9.00 +/- 2.45 h. The terminal elimination half-life (t1/2) and area under the concentration-time curve (AUC) were 16.95 +/- 1.20 h and 69.05 +/- 14.84 micrograms.h/ml, respectively. In the test with dialysis, t1/2 during hemodialysis decreased approximately to one-sixth of that obtained in the test without dialysis, although t1/2 in the latter elimination phase did not differ from that in the nondialysis test. AUC was reduced to 43% of that in the test without dialysis. The fractional removal of cefdinir by hemodialysis was 61%. These findings indicate that clearance of cefdinir is prolonged in patients with renal failure, and cefdinir is well removed by introduction of hemodialysis, although t1/2...Continue Reading

References

Sep 1, 1978·Antimicrobial Agents and Chemotherapy·S J BermanA W Siemsen
Nov 1, 1992·Journal of Clinical Pharmacology·M T BorinC E Halstenson
Apr 1, 1991·Journal of Clinical Pharmacology·W C ShyuR H Barbhaiya
Sep 1, 1990·Clinical Pharmacology and Therapeutics·R H BarbhaiyaK A Pittman
Jan 1, 1986·European Journal of Clinical Pharmacology·R van DalenE Termond
Feb 1, 1982·Antimicrobial Agents and Chemotherapy·D A SpykerW K Bolton

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.